S&P 500   3,935.63 (+0.30%)
DOW   31,482.35 (-0.02%)
QQQ   291.98 (+0.29%)
AAPL   138.31 (-1.78%)
MSFT   255.08 (+0.39%)
FB   193.11 (+0.45%)
GOOGL   2,220.58 (-0.78%)
AMZN   2,174.92 (+1.53%)
TSLA   716.00 (+0.87%)
NVDA   174.07 (+2.77%)
BABA   88.25 (+1.08%)
NIO   16.72 (+5.62%)
AMD   98.35 (+2.15%)
CGC   5.96 (+6.62%)
MU   70.47 (-0.82%)
T   20.18 (-0.25%)
GE   76.16 (+1.28%)
F   13.01 (+1.80%)
DIS   103.85 (-0.43%)
AMC   13.13 (+2.90%)
PFE   50.55 (+0.30%)
PYPL   81.78 (+5.96%)
NFLX   185.37 (+4.62%)
S&P 500   3,935.63 (+0.30%)
DOW   31,482.35 (-0.02%)
QQQ   291.98 (+0.29%)
AAPL   138.31 (-1.78%)
MSFT   255.08 (+0.39%)
FB   193.11 (+0.45%)
GOOGL   2,220.58 (-0.78%)
AMZN   2,174.92 (+1.53%)
TSLA   716.00 (+0.87%)
NVDA   174.07 (+2.77%)
BABA   88.25 (+1.08%)
NIO   16.72 (+5.62%)
AMD   98.35 (+2.15%)
CGC   5.96 (+6.62%)
MU   70.47 (-0.82%)
T   20.18 (-0.25%)
GE   76.16 (+1.28%)
F   13.01 (+1.80%)
DIS   103.85 (-0.43%)
AMC   13.13 (+2.90%)
PFE   50.55 (+0.30%)
PYPL   81.78 (+5.96%)
NFLX   185.37 (+4.62%)
S&P 500   3,935.63 (+0.30%)
DOW   31,482.35 (-0.02%)
QQQ   291.98 (+0.29%)
AAPL   138.31 (-1.78%)
MSFT   255.08 (+0.39%)
FB   193.11 (+0.45%)
GOOGL   2,220.58 (-0.78%)
AMZN   2,174.92 (+1.53%)
TSLA   716.00 (+0.87%)
NVDA   174.07 (+2.77%)
BABA   88.25 (+1.08%)
NIO   16.72 (+5.62%)
AMD   98.35 (+2.15%)
CGC   5.96 (+6.62%)
MU   70.47 (-0.82%)
T   20.18 (-0.25%)
GE   76.16 (+1.28%)
F   13.01 (+1.80%)
DIS   103.85 (-0.43%)
AMC   13.13 (+2.90%)
PFE   50.55 (+0.30%)
PYPL   81.78 (+5.96%)
NFLX   185.37 (+4.62%)
S&P 500   3,935.63 (+0.30%)
DOW   31,482.35 (-0.02%)
QQQ   291.98 (+0.29%)
AAPL   138.31 (-1.78%)
MSFT   255.08 (+0.39%)
FB   193.11 (+0.45%)
GOOGL   2,220.58 (-0.78%)
AMZN   2,174.92 (+1.53%)
TSLA   716.00 (+0.87%)
NVDA   174.07 (+2.77%)
BABA   88.25 (+1.08%)
NIO   16.72 (+5.62%)
AMD   98.35 (+2.15%)
CGC   5.96 (+6.62%)
MU   70.47 (-0.82%)
T   20.18 (-0.25%)
GE   76.16 (+1.28%)
F   13.01 (+1.80%)
DIS   103.85 (-0.43%)
AMC   13.13 (+2.90%)
PFE   50.55 (+0.30%)
PYPL   81.78 (+5.96%)
NFLX   185.37 (+4.62%)
NASDAQ:VIRI

Virios Therapeutics (VIRI) Stock Forecast, Price & News

$4.57
+0.04 (+0.88%)
(As of 05/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.33
$4.67
50-Day Range
$3.31
$5.66
52-Week Range
$3.30
$7.45
Volume
35,900 shs
Average Volume
17,499 shs
Market Capitalization
$38.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.97
30 days | 90 days | 365 days | Advanced Chart
Receive VIRI News and Ratings via Email

Sign-up to receive the latest news and ratings for Virios Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Virios Therapeutics logo

About Virios Therapeutics

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
N/A
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VIRI
Fax
N/A
Employees
5
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
6,781,000
Market Cap
$38.07 million
Optionable
Not Optionable

Company Calendar

Last Earnings
3/17/2022
Today
5/19/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.33 out of 5 stars

Medical Sector

260th out of 1,418 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -













Virios Therapeutics (NASDAQ:VIRI) Frequently Asked Questions

Is Virios Therapeutics a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Virios Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Virios Therapeutics stock.
View analyst ratings for Virios Therapeutics
or view top-rated stocks.

When is Virios Therapeutics' next earnings date?

Virios Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Virios Therapeutics
.

How were Virios Therapeutics' earnings last quarter?

Virios Therapeutics, Inc. (NASDAQ:VIRI) posted its earnings results on Thursday, March, 17th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.52) by $0.02. During the same period in the previous year, the company posted ($1.25) earnings per share.
View Virios Therapeutics' earnings history
.

What price target have analysts set for VIRI?

1 analysts have issued 1 year target prices for Virios Therapeutics' stock. Their forecasts range from $12.00 to $12.00. On average, they expect Virios Therapeutics' share price to reach $12.00 in the next year. This suggests a possible upside of 162.6% from the stock's current price.
View analysts' price targets for Virios Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Virios Therapeutics' key executives?
Virios Therapeutics' management team includes the following people:
  • Mr. Greg Duncan, Chairman & CEO (Age 57, Pay $798.67k)
  • Mr. Ralph D. Grosswald M.P.H., Sr. VP of Operations (Age 53, Pay $274.69k)
  • Dr. R. Michael Gendreau M.D., Ph.D., Chief Medical Officer (Age 66, Pay $459.9k)
  • Ms. Angela Walsh, CFO, SVP of Fin., Corp. Sec. & Treasurer (Age 55)
  • Ms. Carol Duffy Ph.D., Chief Scientific Advisor
When did Virios Therapeutics IPO?

(VIRI) raised $30 million in an IPO on Thursday, December 17th 2020. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO.

What is Virios Therapeutics' stock symbol?

Virios Therapeutics trades on the NASDAQ under the ticker symbol "VIRI."

Who are Virios Therapeutics' major shareholders?

Virios Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.90%), Cetera Advisors LLC (0.53%), UBS Group AG (0.17%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Virios Therapeutics stock include Angela Walsh, Gregory Scott Duncan, Richard James Whitley and William Pridgen.
View institutional ownership trends for Virios Therapeutics
.

Which institutional investors are buying Virios Therapeutics stock?

VIRI stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., UBS Group AG, and Cetera Advisors LLC. Company insiders that have bought Virios Therapeutics stock in the last two years include Angela Walsh, Gregory Scott Duncan, Richard James Whitley, and William Pridgen.
View insider buying and selling activity for Virios Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Virios Therapeutics?

Shares of VIRI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Virios Therapeutics' stock price today?

One share of VIRI stock can currently be purchased for approximately $4.57.

How much money does Virios Therapeutics make?

Virios Therapeutics has a market capitalization of $38.07 million.

How many employees does Virios Therapeutics have?

Virios Therapeutics employs 5 workers across the globe.

What is Virios Therapeutics' official website?

The official website for Virios Therapeutics is www.virios.com.

How can I contact Virios Therapeutics?

The company can be reached via phone at 866 620 8655.

This page was last updated on 5/19/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.